Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer (PITCA)

August 3, 2018 updated by: Institut Claudius Regaud

This is a monocentric, prospective cohort study evaluating the feasibility of a perioperative e-follow-up protocol in patients with ambulatory surgery for breast cancer.

This protocol will be based on:

  • A coordinated ambulatory follow-up performed by a dedicated nurse
  • An electronic follow-up tool used in pre- and post-surgery

Patients will be followed 8 days before the surgery until 30 days after the surgery of breast cancer.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toulouse, France, 31059
        • Institut Claudius Regaud IUCT-ONCOPOLE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Patient eligible for an ambulatory surgery of breast cancer (partial mastectomy with or without lymph node sampling)
  2. Ambulatory surgery planned 10 days or more after inclusion date
  3. Age > or = 18 years old
  4. Affiliated to the french social security system
  5. Patient must provide written informed consent prior to any study-specific procedure or assessment

Exclusion Criteria:

  1. Surgery other than breast cancer surgery in ambulatory (benign breast surgery, other surgical specialities)
  2. Patient who cannot connect to the electronic tool at home (no computer, no tablet computer or no internet connection)
  3. Pregnant or breastfeeding women
  4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
  5. Patient protected by law

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients with breast cancer operated in ambulatory

In pre- and post-surgery:

  • Completion of questionnaires using an electronic tool,
  • Telephone follow-up if necessary between the nurse and the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of patients without failure to the e-follow-up. A failure is defined by absence of connection to the electronic tool and the mismatch between the alert level and severity of complications.
Time Frame: 1.5 months by patient
1.5 months by patient

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient satisfaction to the e-follow-up.
Time Frame: 1.5 months by patient
Satisfaction will be evaluated by questionnaire.
1.5 months by patient
The rate of patients who discontinue the study 8 days before the surgery.
Time Frame: 1.5 months by patient
1.5 months by patient
The number of unplanned visits into the Center after ambulatory surgery in the first 24 hours and during the first 30 days will be assessed for each patient.
Time Frame: 1.5 months by patient
1.5 months by patient
Rate of patients with at least one unplanned visit.
Time Frame: 1.5 months by patient
1.5 months by patient
The time spent by the dedicated nurse for the follow-up protocol management.
Time Frame: 1.5 months by patient
It will be defined as the sum of the time spent at different stages: initial training of patients, tracking of the connections to the tool, tracking of the alerts and telephone contacts.
1.5 months by patient

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dimitri GANGLOFF, Institut Claudius Regaud

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2017

Primary Completion (Actual)

June 29, 2018

Study Completion (Actual)

June 29, 2018

Study Registration Dates

First Submitted

September 18, 2017

First Submitted That Met QC Criteria

September 18, 2017

First Posted (Actual)

September 20, 2017

Study Record Updates

Last Update Posted (Actual)

August 6, 2018

Last Update Submitted That Met QC Criteria

August 3, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Dedicated and coordinated e-follow-up.

Subscribe